IDXX vs. MDLN: IDEXX Laboratories vs. Medline Stock Comparison

Company Profile

IDEXX Laboratories (IDXX) and Medline (MDLN) both belong to the Health Care Equipment & Supplies industry, though IDXX is classified under Health Care Equipment while MDLN falls under Health Care Supplies.

IDEXX Laboratories (IDXX) has been public since June 21, 1991, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. IDEXX Laboratories (IDXX) has a non-negative beta of 1.44.

Risk-Adjusted Performance

Risk-Return Positioning

Both IDXX and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

IDEXX Laboratories (IDXX) at 68.93% clears its industry range for ROE, a sharper capital-efficiency signal than Medline (MDLN) at 4.85%, which is closer to a typical peer reading.

IDEXX Laboratories (IDXX) at 25.36% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

IDEXX Laboratories (IDXX) at 33.14% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: IDEXX Laboratories (IDXX) reports revenue growth of 10.42%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than IDEXX Laboratories (IDXX) at 22.59%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while IDEXX Laboratories (IDXX) at 1.19 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both IDEXX Laboratories (IDXX) at 0.52 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither IDEXX Laboratories (IDXX) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither IDEXX Laboratories (IDXX) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

IDEXX Laboratories (IDXX) at 45.56 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

Medline (MDLN) at 1.70 prices around its industry’s typical P/S ratio, while IDEXX Laboratories (IDXX) at 11.42 clears its benchmark range — IDXX looks notably rich on sales.

Medline (MDLN) at 2.95 sits near its industry’s typical P/B ratio, while IDEXX Laboratories (IDXX) at 28.50 prices above its benchmark range — IDXX looks rich relative to book.

Valuation Metrics